Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.

Literature DB >> 18250190

Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa.

Todd A Davies¹, Wenchi Shang, Karen Bush, Robert K Flamm.

Abstract

Doripenem, a parenteral carbapenem, exhibited high affinity for penicillin-binding protein 2 (PBP2) and PBP3 in Pseudomonas aeruginosa and PBP2 in Escherichia coli, the primary PBPs whose inhibition leads to cell death. This PBP affinity profile correlates with the broad-spectrum gram-negative activity observed with doripenem.

Entities: Chemical Gene Species

Mesh：

Substances：

Year: 2008 PMID： 18250190 PMCID： PMC2292531 DOI： 10.1128/AAC.01529-07

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. BOCILLIN FL, a sensitive and commercially available reagent for detection of penicillin-binding proteins.

Authors: G Zhao; T I Meier; S D Kahl; K R Gee; L C Blaszczak
Journal: Antimicrob Agents Chemother Date: 1999-05 Impact factor: 5.191

2. In vitro antimicrobial activity of doripenem, a new carbapenem.

Authors: Yigong Ge; Matthew A Wikler; Daniel F Sahm; Renée S Blosser-Middleton; James A Karlowsky
Journal: Antimicrob Agents Chemother Date: 2004-04 Impact factor: 5.191

Review 3. Penicillin-binding proteins and bacterial resistance to beta-lactams.

Authors: N H Georgopapadakou
Journal: Antimicrob Agents Chemother Date: 1993-10 Impact factor: 5.191

4. Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: comparison with antibacterial activity and effects upon bacterial morphology.

Authors: N A Curtis; D Orr; G W Ross; M G Boulton
Journal: Antimicrob Agents Chemother Date: 1979-09 Impact factor: 5.191

Review 5. Recent developments in carbapenems.

Authors: Giovanni Bonfiglio; Giovanni Russo; Giuseppe Nicoletti
Journal: Expert Opin Investig Drugs Date: 2002-04 Impact factor: 6.206

6. Comparative in vitro antimicrobial activity of a new carbapenem, doripenem: tentative disc diffusion criteria and quality control.

Authors: Steven D Brown; Maria M Traczewski
Journal: J Antimicrob Chemother Date: 2005-05-04 Impact factor: 5.790

7. Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Authors: Ronald N Jones; Holly K Huynh; Douglas J Biedenbach
Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191

8. In vitro selection of one-step mutants of Streptococcus pneumoniae resistant to different oral beta-lactam antibiotics is associated with alterations of PBP2x.

Authors: F Sifaoui; M D Kitzis; L Gutmann
Journal: Antimicrob Agents Chemother Date: 1996-01 Impact factor: 5.191

9. Binding of monobactams to penicillin-binding proteins of Escherichia coli and Staphylococcus aureus: relation to antibacterial activity.

Authors: N H Georgopapadakou; S A Smith; C M Cimarusti; R B Sykes
Journal: Antimicrob Agents Chemother Date: 1983-01 Impact factor: 5.191

10. Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3.

Authors: Y Sumita; M Fukasawa
Journal: J Antimicrob Chemother Date: 1995-07 Impact factor: 5.790

41 in total

1. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.

Authors: Hajira Bilal; Phillip J Bergen; Tae Hwan Kim; Seung Eun Chung; Anton Y Peleg; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer
Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191

2. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.

Authors: Rajnikant Sharma; Saloni Patel; Cely Abboud; John Diep; Neang S Ly; Jason M Pogue; Keith S Kaye; Jian Li; Gauri G Rao
Journal: Int J Antimicrob Agents Date: 2016-12-23 Impact factor: 5.283

3. In Vitro Activity of Tebipenem (SPR859) against Penicillin-Binding Proteins of Gram-Negative and Gram-Positive Bacteria.

Authors: Evelyne Lacasse; Eric Brouillette; Audrey Larose; Thomas R Parr; Aileen Rubio; François Malouin
Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191

4. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Authors: Gauri G Rao; Neang S Ly; Jürgen B Bulitta; Rachel L Soon; Marie D San Roman; Patricia N Holden; Cornelia B Landersdorfer; Roger L Nation; Jian Li; Alan Forrest; Brian T Tsuji
Journal: J Antimicrob Chemother Date: 2016-08-03 Impact factor: 5.790

5. Binding of faropenem and other beta-lactam agents to penicillin-binding proteins of pneumococci with various beta-lactam susceptibilities.

Authors: Klaudia Kosowska-Shick; Pamela McGhee; Peter C Appelbaum
Journal: Antimicrob Agents Chemother Date: 2009-02-23 Impact factor: 5.191

Review 6. Newer antibacterial drugs for a new century.

Authors: Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal: Expert Opin Investig Drugs Date: 2010-02 Impact factor: 6.206

7. Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae.

Authors: James Albiero; Sherwin K B Sy; Josmar Mazucheli; Silvana Martins Caparroz-Assef; Bruno Buranello Costa; Janio Leal Borges Alves; Ana Cristina Gales; Maria Cristina Bronharo Tognim
Journal: Antimicrob Agents Chemother Date: 2016-06-20 Impact factor: 5.191